Trade with Eva: Analytics in action >>

Thursday, March 12, 2026

Alliance Laundry Holdings (ALH) reported earnings on Thur 12 March 26 (b/o)

 
ALH





Alliance Laundry Systems beats by $0.01, beats on revs; guides FY26 revs in-line
  • Reports Q4 (Dec) earnings of $0.24 per share, excluding non-recurring items, $0.01 better than the FactSet Consensus of $0.23; revenues rose 10.1% year/year to $434.9 mln vs the $419.91 mln FactSet Consensus.
  • Co issues in-line guidance for FY26, sees FY26 revs of +5-7% yr/yr to ~$1.78-1.83 bln vs. $1.8 bln FactSet Consensus.

Alliance Laundry Systems -10% trades to new post-IPO low as top line growth slows in FY26 
  • Alliance Laundry Systems (ALH) is still early in its life as a public company, and today's sell-off suggests investors were hoping for stronger growth signals following its October 2025 IPO.
  • While the company delivered modest EPS upside and more meaningful revenue upside for Q4, the bigger focus appears to be on the outlook. FY26 revenue growth guidance of +5-7% represents a notable slowdown from the +13% growth delivered in FY25, and that deceleration is catching investor attention, particularly since last year's gains were largely organic rather than acquisition-driven.
  • Management continues to emphasize the durability of the commercial laundry market, noting that laundry services are a non-discretionary part of everyday life and tend to perform consistently across economic cycles. That stability is one reason the company believes its business offers dependable long-term growth and downside protection.
  • At the same time, Alliance Laundry highlights its leadership position as the largest pure-play commercial laundry equipment manufacturer globally, supported by brands such as Speed Queen and UniMac, along with a global manufacturing and engineering footprint spanning three continents.
  • Even so, investors appear to be taking a cautious stance as the company adjusts to public market expectations. The narrative around scale advantages and strong customer demand remains intact, but the guidance implies that growth is normalizing following a particularly strong FY25. As a relatively new public company, Alliance Laundry may need to deliver a few more quarters of consistent execution before investors grow comfortable with its longer-term growth trajectory.

Wednesday, March 11, 2026

Viant Technology (DSP) reported earnings on Wed 11 March 26 (a/h)

Viant was launched by brothers Tim, Chris and Russ Vanderhook in 1999. The company acquired social networking company Myspace in 2011. Later that year it helped start connected TV platform Xumo, which was acquired by Comcast in 2020.
IPO Feb 10, 21; ticker DSP 







Chris and Tim Vanderhook, COO and CEO of Viant

Viant posts record Q4 2025 with EPS $0.31 (+210% YoY) and revenue $64.6M (+19% YoY), beating guidance and estimates, launches AI Outcomes product

  • Q4 revenue and contribution ex-TAC beat guidance, with ex-political growth accelerating sharply.
  • Full-year 2025 revenue and adjusted EBITDA exceeded guidance with high-teens growth and nearly 250 bps EBITDA margin expansion.
  • Upbeat Q1 2026 guide implies ~20% revenue growth but slower Q4-like momentum seasonally.
  • Management expects sequential growth acceleration through 2026 from new clients, Outcomes, and political.


The company, which has about 300 employees, competes with players like The Trade Desk and with part of Google’s ad tech business. The software is used by marketers and their ad agencies to centralize buying, planning and measurement of advertising across channels like desktop, mobile, connected TV, streaming audio and digital billboards.

Monday, March 9, 2026

Daily NYSI – March 2026

  • Thur 3/12/26





S&P Mid Cap 400: +1.2% YTD
Russell 2000: +0.3% YTD
S&P 500: -2.5% YTD
DJIA: -2.9% YTD
Nasdaq Composite: -4.0% YTD


===Xenon Pharma (XENE) : Phase 3 X-TOLE2 azetukalner trial in focal onset seizures meets primary and key secondary endpoints

 


Xenon reports topline data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures
VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS). Azetukalner is a novel, potent, KV7 potassium channel opener currently in clinical development for epilepsy and depression.

  • X-TOLE2 results showed strong efficacy and favorable safety profile for azetukalner in focal onset seizures.
  • Xenon plans to submit a U.S. FDA NDA for azetukalner in the third quarter of 2026.